A Phase 4 interventional study of Paricalcitol and Darbepoetin alfa in Moderate to Severe Secondary Hyperparathyroidism and Stage 5 Chronic Kidney Diseases, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-30.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing paricalcitol in Renal Insufficiency, Chronic — none open to participants now, none under way, none of them phase 3. paricalcitol · Renal Insufficiency, Chronic.
Among the 33 studies testing paricalcitol in Renal Insufficiency, Chronic, this one is the 15th largest by enrollment, is one of 2 that started in 2012, is one of 10 in phase 4, and was the 29th registered.
3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →None of the 33 studies testing paricalcitol in Renal Insufficiency, Chronic is open now. The open studies under Renal Insufficiency, Chronic, anywhere →
paricalcitol: first FDA approval 1998 (ZEMPLAR). What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 12 · Phase 4 10
First in 2002; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is below the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 60 across the 33 interventional studies. Of the 32 that completed or were terminated, 19 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
19 studies in Renal Insufficiency, Chronic by AbbVie: none open now, none under way, none of them phase 3. Of 19 finished, 14 (74%) have results posted.
Among the 19 studies in Renal Insufficiency, Chronic by AbbVie, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2012, is one of 3 in phase 4, and was the 16th registered.
AbbVie’s Renal Insufficiency, Chronic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing paricalcitol in Renal Insufficiency, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 19 in Renal Insufficiency, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the effect of PTH lowering on erythropoietin consumption in calcitriol-resistant patients with stage 5 chronic kidney disease.
Inclusion Criteria: A subject will only be included if all the following entry criteria are met:
Exclusion Criteria:
A subject will be excluded from the study if he/she meets any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received paricalcitol intravenously during hemodialysis until serum intact parathyroid hormone (iPTH) levels were below 150 pg/mL or for up to 6 months. Paricalcitol dose was based on iPTH levels and was titrated to maintain iPTH levels between 150-300 pg/mL. Participants may have also received routine darbepoetin alfa to treat anemia.
Drug: Paricalcitol · Drug: Darbepoetin alfa
Paricalcitol was administered by intravenous bolus. The initial dose was calculated according to the following formula: \[Paricalcitol (µg) = iPTH (pg/mL) / 80\]. Subsequent doses were determined based on iPTH, calcium and phosphorus levels.
Also known as: ABT-358, Zemplar
Routine darbepoetin alfa use was allowed when transferrin saturation (TSAT) was ≥ 20% and ferritin ≥ 200 μg/L, and hemoglobin level \< 11.5 g/dL. The initial dose was 0.25 to 0.75 µg/kg/week, and the maintenance dose was 0.13 to 0.35 µg/kg/week. Target hemoglobin level was between 10 to 11.5 g/dL.
Mean Erythropoietin Dose Per Visit
The requirement of erythropoietin (EPO) treatment to maintain serum hemoglobin levels between 10 to 11.5 g/dL during the study was assessed by analysis of the dose of darbepoetin alfa used at baseline and during each month of the study. The mean EPO dosage per injection for each study month is reported.
Time frame: Baseline and Months 1, 2, 3, 4, 5 and 6
Mean Scores of Short Form Health Survey 36 (SF-36) Questionnaire
The Medical Outcome Study Short Form 36-Item Health Survey (SF-36) is a self-administered questionnaire that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains. The domains include physical (physical functioning, role limitations due to physical health (role-physical), general health perceptions and pain) and mental domains (energy/fatigue (vitality), social functioning, emotional well-being (mental health), and role limitations due to emotional problems (role emotional)). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning.
Time frame: Baseline and Month 6
Mean Intact Parathyroid Hormone (iPTH) Level at Baseline and Month 6
Time frame: Baseline and Month 6
Mean Calcium Level at Baseline and Month 6
Time frame: Baseline and Month 6
Mean Phosphorus Level at Baseline and Month 6
Time frame: Baseline and Month 6
Mean Alkaline Phosphatase Level at Baseline and Month 6
Time frame: Baseline and Month 6
Vitamin B12 Levels
Vitamin B12 levels were categorized according to the following laboratory reference ranges: Low: \< 200 pg/mL Normal: 200 - 950 pg/mL High: \> 950 pg/mL
Time frame: Baseline and month 6
Folic Acid Levels
Folic acid levels were categorized according to the following laboratory reference ranges: Low: \< 4.6 ng/mL Normal: 4.6 - 18.7 ng/mL High: \> 18.7 ng/mL
Time frame: Baseline and month 6
Mean High Sensitivity C-reactive Protein (hsCRP) Level at Baseline and Month 6
Time frame: Baseline and Month 6
Mean Fibroblast Growth Factor-23 (FGF-23) Level at Baseline and Month 6
Time frame: Baseline and Month 6
Number of Participants With Adverse Events
Serious adverse events were any adverse events meeting any of the following criteria: * An event that resulted in the death of a participant; * An event that, in the opinion of the investigator, would have resulted in immediate fatality if medical intervention had not been taken (life-threatening); * Resulted in an admission to the hospital for any length of time or prolonged hospital stay; * An anomaly detected at or after birth, or any anomaly that results in fetal loss; * An event that resulted in a condition that substantially interfered with the activities of daily living; * An important medical event that may not be immediately life-threatening or result in death or hospitalization, but based on medical judgment may have jeopardized the participant and may have required medical or surgical intervention to prevent any of the outcomes listed above. Adverse events were assessed by the investigator for possible relationship to study drug.
Time frame: From the time of study drug administration until 4 weeks after the discontinuation of the study drug; up to 7 months.
This study was conducted at 7 centers in Turkey.
| Milestone | Paricalcitol |
|---|---|
| Started | 65 |
| Completed | 49 |
| Not completed | 16 |
| Withdrew: Lost to follow-up | 7 |
| Withdrew: Adverse event | 5 |
| Withdrew: Death | 1 |
| Withdrew: Did not meet eligibility criteria | 3 |
The requirement of erythropoietin (EPO) treatment to maintain serum hemoglobin levels between 10 to 11.5 g/dL during the study was assessed by analysis of the dose of darbepoetin alfa used at baseline and during each month of the study. The mean EPO dosage per injection for each study month is reported.
| µg | Paricalcitol |
|---|---|
| Baseline | 35.8 ± 15.0 |
| Month 1 | 22.2 ± 20.0 |
| Month 2 | 22.7 ± 21.3 |
| Month 3 | 4.7 ± 4.5 |
| Month 4 | 7.2 ± 6.2 |
| Month 5 | 17.3 ± 19.5 |
| Month 6 | 21.8 ± 19.7 |
The Medical Outcome Study Short Form 36-Item Health Survey (SF-36) is a self-administered questionnaire that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains. The domains include physical (physical functioning, role limitations due to physical health (role-physical), general health perceptions and pain) and mental domains (energy/fatigue (vitality), social functioning, emotional well-being (mental health), and role limitations due to emotional problems (role emotional)). The individual domain scores are calculated and transformed to range from 0 to 100, with higher scores indicating a better level of functioning.
| units on a scale | Paricalcitol |
|---|---|
| Physical Function - Baseline | 51.7 ± 26.3 |
| Physical Function - Month 6 | 51.5 ± 30.1 |
| Role Physical - Baseline | 38.5 ± 45.2 |
| Role Physical - Month 6 | 44.3 ± 46.5 |
| Role Emotional - Baseline | 52.8 ± 46.0 |
| Role Emotional - Month 6 | 54.2 ± 47.0 |
| Vitality - Baseline | 47.4 ± 16.5 |
| Vitality - Month 6 | 45.2 ± 17.0 |
| Mental Health - Baseline | 54.5 ± 12.6 |
| Mental Health - Month 6 | 52.7 ± 15.2 |
| Social Functioning - Baseline | 59.6 ± 20.7 |
| Social Functioning - Month 6 | 55.5 ± 26.3 |
| Pain - Baseline | 61.3 ± 26.6 |
| Pain - Month 6 | 60.5 ± 25.0 |
| General Health - Baseline | 47.0 ± 16.9 |
| General Health - Month 6 | 44.4 ± 22.3 |
| pg/mL | Paricalcitol |
|---|---|
| Baseline | 918.0 ± 585.9 |
| Month 6 | 692.5 ± 413.4 |
| mg/mL | Paricalcitol |
|---|---|
| Baseline | 8.81 ± 0.95 |
| Month 6 | 9.29 ± 0.86 |
| mg/mL | Paricalcitol |
|---|---|
| Baseline | 4.87 ± 1.11 |
| Month 6 | 5.47 ± 1.22 |
| U/L | Paricalcitol |
|---|---|
| Baseline | 225.7 ± 170.1 |
| Month 6 | 172.9 ± 147.6 |
Vitamin B12 levels were categorized according to the following laboratory reference ranges: Low: \< 200 pg/mL Normal: 200 - 950 pg/mL High: \> 950 pg/mL
| Participants | Baseline | Month 6 |
|---|---|---|
| Low | 2 | 0 |
| Normal | 13 | 22 |
| High | 33 | 24 |
Folic acid levels were categorized according to the following laboratory reference ranges: Low: \< 4.6 ng/mL Normal: 4.6 - 18.7 ng/mL High: \> 18.7 ng/mL
| Participants | Baseline | Month 6 |
|---|---|---|
| Low | 1 | 4 |
| Normal | 25 | 25 |
| High | 22 | 17 |
| mg/mL | Paricalcitol |
|---|---|
| Baseline | 11.8 ± 14.1 |
| Month 6 | 14.4 ± 20.7 |
| kRU/L | Paricalcitol |
|---|---|
| Baseline | 6267 ± 5967 |
| Month 6 | 11340 ± 13450 |
Serious adverse events were any adverse events meeting any of the following criteria: * An event that resulted in the death of a participant; * An event that, in the opinion of the investigator, would have resulted in immediate fatality if medical intervention had not been taken (life-threatening); * Resulted in an admission to the hospital for any length of time or prolonged hospital stay; * An anomaly detected at or after birth, or any anomaly that results in fetal loss; * An event that resulted in a condition that substantially interfered with the activities of daily living; * An important medical event that may not be immediately life-threatening or result in death or hospitalization, but based on medical judgment may have jeopardized the participant and may have required medical or surgical intervention to prevent any of the outcomes listed above. Adverse events were assessed by the investigator for possible relationship to study drug.
| participants | Paricalcitol |
|---|---|
| Non-serious adverse events | 9 |
| Serious adverse events | 11 |
| Treatment-related adverse events | 0 |
| Fatal adverse events | 3 |
Collected over 6 months. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Paricalcitol | — | 11/65 (16.9%) | 1/65 (1.5%) |
| Event | Paricalcitol |
|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/65 |
| AstheniaGeneral disorders | 2/65 |
| Renal transplantSurgical and medical procedures | 2/65 |
| PyrexiaGeneral disorders | 2/65 |
| PalpitationsCardiac disorders | 2/65 |
| Arteriovenous fistula thrombosisInjury, poisoning and procedural complications | 2/65 |
| NephrectomySurgical and medical procedures | 1/65 |
| FatigueGeneral disorders | 1/65 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 1/65 |
| AscitesGastrointestinal disorders | 1/65 |
| Event | Paricalcitol |
|---|---|
| Arteriovenous fistula site haemorrhageInjury, poisoning and procedural complications | 1/65 |
| NasopharyngitisInfections and infestations | 1/65 |
| Arteriovenous fistulaVascular disorders | 1/65 |
| HeadacheNervous system disorders | 1/65 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/65 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 1/65 |
| VertigoEar and labyrinth disorders | 1/65 |
| DizzinessNervous system disorders | 1/65 |
| Chest painGeneral disorders | 1/65 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/65 |
The per-protocol analysis set which included participants who completed the study according to the protocol. One patient was enrolled into the study under protocol version 1.0 and was not included in the per-protocol analysis set due to subsequent major changes to the protocol.
| Age, Continuous(years) | Paricalcitol |
|---|---|
| Mean | 49.6 ± 16.7 |
| Sex: Female, Male(Participants) | Paricalcitol |
|---|---|
| Female | 26 |
| Male | 22 |
No study locations are listed for this record.
Ran from May 2012 to primary completion in Apr 2016, 46 months.
Results were first posted in May 2017, 1 year 1 month after primary completion.
Of 117 phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 65. This study's 46 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Paricalcitol · Darbepoetin alfa
Renal Insufficiency, Chronic →
AbbVie (prior sponsor, Abbott) →